VISIT OUR LINKS: https://linktr.ee/manonthemounjaro TIMESTAMPS: 0:10 Welcome to On The Pen. We just wrapped up listening to the 2025 Q2 Novo Nordisk earnings call... 1:14 Compounded semaglutide is the scapegoat for Novo’s sales slump — let’s unpack it... 2:34 Wegovy growth is slowing, and Novo blames mass compounding in the U.S. despite FDA deadline... 4:10 CVS makes Wegovy the only GLP-1 on formulary for obesity — what that means for access... 6:05 NovoCare Pharmacy struggles to gain traction — only 10% of Wegovy Rx are cash... 7:52 Oral semaglutide for obesity is coming in 2026 with no supply restrictions expected... 9:20 Amycretin enters Phase 3: up to 24% weight loss, both oral and injectable in AMAZE program... 11:08 CagriSema Phase 3b “REDEFINE 11” is now live — testing higher doses and longer use... 12:36 Novo confirms tirzepatide failed to beat dulaglutide for heart protection — semaglutide remains best in class... 14:18 CEO Mike Doustdar’s vision: focus, faster execution, and reallocating budget to obesity pipeline... 15:59 Semaglutide’s unique cardiovascular data explained — FLOW and SUSTAIN-6 trials revisited... 17:46 Wegovy cash channel expansion plans — including Ozempic coming to NovoCare soon... 19:10 What patients need to know when talking to their doctor — current options and what’s next... DESCRIPITON: Novo Nordisk Q2 2025 Earnings: What It Means for GLP-1s, Compounded Semaglutide, Amycretin & Obesity Treatment In this breakdown of Novo Nordisk’s Q2 2025 earnings call, I cover the biggest takeaways for anyone using or considering GLP-1 medications like Ozempic, Wegovy, Rybelsus, and semaglutide for obesity, type 2 diabetes, and related comorbidities. 📉 Novo just lowered their full-year guidance — but why? 💊 1 million patients in the U.S. are estimated to still be on compounded GLP-1 medications, despite the May 22 FDA ruling. Novo says it’s illegal, and they’re calling out pharmacies and telehealth clinics. 🚨 Legal pressure is ramping up. Lawsuits are likely. 🌎 Wegovy is now the ONLY GLP-1 covered for obesity on CVS’s national formulary. This could change everything. 🧪 And perhaps the most exciting update? Novo’s next-gen obesity drug, amycretin, is heading into Phase 3 trials — showing up to 24.3% weight loss in earlier studies. Yes, it’s both oral and injectable. You'll also learn about: The future of oral semaglutide (expected launch in 2026, no supply restrictions) The battle between branded and compounded semaglutide CagriSema’s continued advancement in obesity care Why semaglutide’s cardiovascular benefits are still unmatched, even versus tirzepatide (Zepbound) What new CEO Mike Doustdar plans to do differently This video is for patients, clinicians, advocates, and anyone needing confidence when talking to their doctor about treating obesity today — and what’s coming next.

Breaking News Today from the Trump administration on the cost of GLP-1

Breaking News Today from the Trump administration on the cost of GLP-1 VISIT OUR LINKS: https://linktr.ee/manonthemounjaro

🚨 In this episode of On The Pen, we break down a brand-new mouse study presented at ENDO 2025 that’s turning heads — Zepbound didn’t just help obese mice lose fat, it shrunk their breast tumors. That’s right. For the second time in a week, a GLP-1 medication is showing potential disease-fighting power beyond weight loss. We cover: • How the study was designed • What the results mean for women with obesity • Why this builds on the heart protection data we just reported This is not just about pounds lost. This is about changing the internal environment that fuels disease. Don’t miss this one. 👉 Subscribe for more GLP-1 news, explained from a patient’s perspective. 💬 Drop your thoughts in the comments — especially if this hits close to home. 📰 Read the full breakdown on Substack: [link] #Zepbound #GLP1 #ObesityMedicine #BreastCancer #ENDO2025 #OnThePen #PatientAdvocacy #Mounjaro #Tirzepatide #CancerResearch #GLP1News

All Referenced Links: https://linktr.ee/manonthemounjaro In this episode of On The Pen: Faces of the Fight, I sit down with Connecticut State Senator Matt Lesser, the lawmaker behind one of the boldest health policy moves in recent memory. We talk about Connecticut’s newly passed bipartisan prescription drug affordability bill and the groundbreaking provision buried inside it — a plan to petition the federal government for permission to manufacture their own GLP-1 medications like Ozempic. Senator Lesser explains how this little-known federal law could allow Connecticut to override pharmaceutical patents in the public interest, why the state is spending over 150 million dollars a year on GLP-1s, and how this approach could bring drug prices down not just in Connecticut, but potentially nationwide. We also dig into timelines, political strategy, and the real-world implications of a state trying to break Big Pharma’s pricing model. If you care about access, affordability, and the future of obesity treatment in America, this is one you don’t want to miss.

https://www.getclaimable.com/otp Code OTP10 Saves 10% Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro #zepbound #insurance #cvscaremark

Full article: https://substack.com/@onthepen/note/c-130749661?r=4n3ng9&utm_medium=ios&utm_source=notes-share-action Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro #alzheimer #ozempic #semaglutide

Full Study: https://www.nature.com/articles/s41591-025-03774-9 Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro #zepbound #mounjaro #foodnoise

Get obesity News to Your inbox: https://www.obesity.news Visit All Our Links: https://www.linktr.ee/manonthemounjaro #retaturtide #cagrisema #onthepen

#ADA2025 #Type2Diabetes #DietSoda Get All The News! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro

JOIN THE FIGHT HTTP://WWW.ONTHEPEN.SUBSTACK.COM

See all my links: https://linktr.ee/manonthemounjaro

CVS announces major partnership with Novo Nordisk as Lilly announces Q! 2025 earnings. Dave covers it all in today's breakdown. Join the Substack: https://substack.com/@onthepen WAYS TO SUPPORT MY WORK ⬇️ 💊 OVER THE COUNTER ORAL PEPTIDE SUPPLIMENTS: BPC-157 // Can’t Weight // TB4-FRAG // KPV Sign up here and use code “OTP10” to save 10% https://integrativepeptides.com/OTP WHY I TRUST INTEGRATIVE PEPTIDES: 🇺🇸 Made in the USA 📋 CGMP Compliant (FDA oversight of their products) 🧑‍⚕️Trusted and Sold By Doctors and Clinics all over the USA 📕 GET MY BOOK! Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp https://amzn.to/4gAXrz4 SOCIALS: 📸 : https://www.instagram.com/onthepen.official/profilecard/?igsh=dTRhY3JkYWo1bTIx 🇨🇳: https://www.tiktok.com/@manonthemounjaro?_t=ZP-8sr5PrUuPQl&_r=1 👾: https://discord.gg/ZHeUh7WV 📺: https://youtube.com/@ManOnTheMounjaro?feature=shared ❌: https://x.com/manonthepen?s=21 💻: https://www.onthepen.com https://www.youtube.com/playlist?list=PLtOcNl0C8quVo0I2YODK-q7cHh4y1r2yB Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit my website at onthepen.com. 🎙️ New to streaming or looking to level up? Check out StreamYard and get $10 discount! 😍 https://streamyard.com/pal/d/6163227593146368

We’ve said it for a long time. Covering GLP-1 medications isn’t just the right thing to do for your employees. It’s the smart thing. Now, we have the data to back it up. Join the Substack: https://substack.com/@onthepen WAYS TO SUPPORT MY WORK ⬇️ 💊 OVER THE COUNTER ORAL PEPTIDE SUPPLEMENTS: BPC-157 // Can’t Weight // TB4-FRAG // KPV Sign up here and use code “OTP10” to save 10% https://integrativepeptides.com/OTP WHY I TRUST INTEGRATIVE PEPTIDES: 🇺🇸 Made in the USA 📋 CGMP Compliant (FDA oversight of their products) 🧑‍⚕️Trusted and Sold By Doctors and Clinics all over the USA 📕 GET MY BOOK! Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp https://amzn.to/4gAXrz4 SOCIALS: 📸 : https://www.instagram.com/onthepen.official/profilecard/?igsh=dTRhY3JkYWo1bTIx 🇨🇳: https://www.tiktok.com/@manonthemounjaro?_t=ZP-8sr5PrUuPQl&_r=1 👾: https://discord.gg/ZHeUh7WV 📺: https://youtube.com/@ManOnTheMounjaro?feature=shared ❌: https://x.com/manonthepen?s=21 💻: https://www.onthepen.com https://www.youtube.com/playlist?list=PLtOcNl0C8quVo0I2YODK-q7cHh4y1r2yB Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit my website at onthepen.com.

Eli Lilly has filed lawsuits against four large telehealth companies including Mochi Health, Fella and Delilah, Willow Health Services, and Henry Meds. The claim? These platforms are selling unapproved versions of tirzepatide, the same active ingredient in Mounjaro and Zepbound. In this video, we break down what Lilly is saying, why these lawsuits matter, and what this means for patients who rely on affordable access to GLP 1 medications. We also talk about Lilly’s claim that these companies are influencing prescribing decisions. From fast tracked patient evaluations to templated scripts that push compounded meds, Lilly is calling out what it says is a sales driven model that puts patient safety at risk. As the FDA shortage status ends and the legal system kicks into gear, the future of compounded GLP 1 meds hangs in the balance. If you are a patient, provider, or advocate in this space, you need to understand what is happening. #tirzepatide #lawsuit #EliLilly #compounds #mounjaro, Zepbound, GLP 1 medications, compounded tirzepatide, telehealth, Henry Meds, Mochi Health, FDA tirzepatide update, weight loss medication access, obesity treatment news

The Knapp family was featured in a health.com video! Watch it Here: https://www.health.com/beyond-obesity-glp1-8685599 WAYS TO SUPPORT MY WORK ⬇️ 💊 OVER THE COUNTER ORAL PEPTIDE SUPPLIMENTS: BPC-157 // Can’t Weight // TB4-FRAG // KPV Sign up here and use code “OTP10” to save 10% https://integrativepeptides.com/OTP WHY I TRUST INTEGRATIVE PEPTIDES: 🇺🇸 Made in the USA 📋 CGMP Compliant (FDA oversight of their products) 🧑‍⚕️Trusted and Sold By Doctors and Clinics all over the USA 📕 GET MY BOOK! Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp https://amzn.to/4gAXrz4 SOCIALS: 📸 : https://www.instagram.com/onthepen.official/profilecard/?igsh=dTRhY3JkYWo1bTIx 🇨🇳: https://www.tiktok.com/@manonthemounjaro?_t=ZP-8sr5PrUuPQl&_r=1 👾: https://discord.gg/ZHeUh7WV 📺: https://youtube.com/@ManOnTheMounjaro?feature=shared ❌: https://x.com/manonthepen?s=21 💻: https://www.onthepen.com #orforglipron #ozempic #mounjaro

WAYS TO SUPPORT MY WORK ⬇️ 💊 OVER THE COUNTER ORAL PEPTIDE SUPPLIMENTS: BPC-157 // Can’t Weight // TB4-FRAG // KPV Sign up here and use code “OTP10” to save 10% https://integrativepeptides.com/OTP WHY I TRUST INTEGRATIVE PEPTIDES: 🇺🇸 Made in the USA 📋 CGMP Compliant (FDA oversight of their products) 🧑‍⚕️Trusted and Sold By Doctors and Clinics all over the USA 📕 GET MY BOOK! Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp https://amzn.to/4gAXrz4 SOCIALS: 📸 : https://www.instagram.com/onthepen.official/profilecard/?igsh=dTRhY3JkYWo1bTIx 🇨🇳: https://www.tiktok.com/@manonthemounjaro?_t=ZP-8sr5PrUuPQl&_r=1 👾: https://discord.gg/ZHeUh7WV 📺: https://youtube.com/@ManOnTheMounjaro?feature=shared ❌: https://x.com/manonthepen?s=21 💻: https://www.onthepen.com #danuglipron #orforglipron #pfizer #ozempic #mounjaro #onthepen

See all my links: https://linktr.ee/manonthemounjaro